Blood Pressure During Rate Control in Patients With Tachycardic Atrial Fibrillation at the Emergency Department

Last updated: September 16, 2019
Sponsor: Medical University of Vienna
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Atrial Fibrillation

Arrhythmia

Dysrhythmia

Treatment

N/A

Clinical Study ID

NCT04005482
MUVienna 1568/2014
  • Ages 18-120
  • All Genders

Study Summary

The aim of this study is to analyse blood pressure during rate control therapy in patients with tachycardic atrial fibrillation in a real-world emergency cohort.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age > 18 years

  • Atrial fibrillation or atrial flutter and heart rate ≥ 110 bpm

  • Indication for rate control

  • Informed consent

Exclusion

Exclusion Criteria:

• Inclusion criteria not met

Study Design

Total Participants: 140
Study Start date:
September 20, 2019
Estimated Completion Date:
July 20, 2021

Study Description

Atrial fibrillation (AF) is the primary clinical problem in 3.3% to 10.0 % emergency department (ED) admissions. Rate control is an integral part of the management of symptomatic tachycardic AF patients.

According to the recent guidelines beta-blockers, digoxin, the calcium channel blockers diltiazem and verapamil, amiodarone or combination therapy should be considered for rate control. Haemodynamic side-effects in particular hypotension may occur. Heart rate and blood pressure behavior in an ED population during rate control therapy in patients with tachycardic atrial fibrillation will be analysed.